MAPT and Alzheimer disease: Currently five biomarkers for AD have been used for evaluation of disease and monitoring of disease progression (Jack et al., 2010): CSF levels of Aβ42, CSF levels of total tau and p-tau181 and p-tau231, structural imaging (CT and MRI) and functional imaging (PET with [18F]FDG).